Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation: Case report

Baldeep Wirk, J. R. Wingard

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Strongyloides stercoralis is endemic in tropical, subtropical, and even temperate regions, and infects up to 100 million people worldwide. The diagnosis of strongyloidiasis can be difficult because of intermittent larval output in stool and nonspecific symptoms with mild peripheral eosinophilia. In this case report, a patient with acute myelogenous leukemia underwent peripheral blood hematopoietic stem cell transplantation (HSCT) and was subsequently diagnosed with strongyloidiasis. Strongyloidiasis should be considered in immunocompromised patients from endemic areas who have unexplained peripheral eosinophilia. If screening tests are positive for S. stercoralis or if a patient has unexplained eosinophilia with even a remote history of travel to or residence in endemic areas, then ivermectin should be given before HSCT to prevent often fatal hyperinfection syndrome from occurring after HSCT.

Original languageEnglish (US)
Pages (from-to)143-148
Number of pages6
JournalTransplant Infectious Disease
Volume11
Issue number2
DOIs
StatePublished - Apr 1 2009

Fingerprint

Strongyloidiasis
Strongyloides stercoralis
Hematopoietic Stem Cell Transplantation
Eosinophilia
Peripheral Blood Stem Cell Transplantation
Ivermectin
Immunocompromised Host
Acute Myeloid Leukemia

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Transplantation

Cite this

@article{726efe0e56d04b58889a5d53f67da204,
title = "Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation: Case report",
abstract = "Strongyloides stercoralis is endemic in tropical, subtropical, and even temperate regions, and infects up to 100 million people worldwide. The diagnosis of strongyloidiasis can be difficult because of intermittent larval output in stool and nonspecific symptoms with mild peripheral eosinophilia. In this case report, a patient with acute myelogenous leukemia underwent peripheral blood hematopoietic stem cell transplantation (HSCT) and was subsequently diagnosed with strongyloidiasis. Strongyloidiasis should be considered in immunocompromised patients from endemic areas who have unexplained peripheral eosinophilia. If screening tests are positive for S. stercoralis or if a patient has unexplained eosinophilia with even a remote history of travel to or residence in endemic areas, then ivermectin should be given before HSCT to prevent often fatal hyperinfection syndrome from occurring after HSCT.",
author = "Baldeep Wirk and Wingard, {J. R.}",
year = "2009",
month = "4",
day = "1",
doi = "10.1111/j.1399-3062.2008.00360.x",
language = "English (US)",
volume = "11",
pages = "143--148",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "2",

}

Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation : Case report. / Wirk, Baldeep; Wingard, J. R.

In: Transplant Infectious Disease, Vol. 11, No. 2, 01.04.2009, p. 143-148.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation

T2 - Case report

AU - Wirk, Baldeep

AU - Wingard, J. R.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Strongyloides stercoralis is endemic in tropical, subtropical, and even temperate regions, and infects up to 100 million people worldwide. The diagnosis of strongyloidiasis can be difficult because of intermittent larval output in stool and nonspecific symptoms with mild peripheral eosinophilia. In this case report, a patient with acute myelogenous leukemia underwent peripheral blood hematopoietic stem cell transplantation (HSCT) and was subsequently diagnosed with strongyloidiasis. Strongyloidiasis should be considered in immunocompromised patients from endemic areas who have unexplained peripheral eosinophilia. If screening tests are positive for S. stercoralis or if a patient has unexplained eosinophilia with even a remote history of travel to or residence in endemic areas, then ivermectin should be given before HSCT to prevent often fatal hyperinfection syndrome from occurring after HSCT.

AB - Strongyloides stercoralis is endemic in tropical, subtropical, and even temperate regions, and infects up to 100 million people worldwide. The diagnosis of strongyloidiasis can be difficult because of intermittent larval output in stool and nonspecific symptoms with mild peripheral eosinophilia. In this case report, a patient with acute myelogenous leukemia underwent peripheral blood hematopoietic stem cell transplantation (HSCT) and was subsequently diagnosed with strongyloidiasis. Strongyloidiasis should be considered in immunocompromised patients from endemic areas who have unexplained peripheral eosinophilia. If screening tests are positive for S. stercoralis or if a patient has unexplained eosinophilia with even a remote history of travel to or residence in endemic areas, then ivermectin should be given before HSCT to prevent often fatal hyperinfection syndrome from occurring after HSCT.

UR - http://www.scopus.com/inward/record.url?scp=64249104456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249104456&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3062.2008.00360.x

DO - 10.1111/j.1399-3062.2008.00360.x

M3 - Article

C2 - 19144095

AN - SCOPUS:64249104456

VL - 11

SP - 143

EP - 148

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 2

ER -